INT J CLIN EXP PATHO 润色咨询

International Journal of Clinical and Experimental Pathology

出版年份：2008 年文章数：7250 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：4.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2025-10-09 ms7000000850384226 来自北京

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤免疫
    经验分享：7.29投稿，9.21小修，目前还没二审消息

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2025-08-31 ms7000002977722171 来自上海

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：临床病理机制
    经验分享：今年1月8号投了稿
    1月15号收到格式修改提醒，调整后当天重新提交，
    1月20号状态更新为 With editor
    1月29号进入 Under review 阶段。
    3月1号显示 Required reviews complete，
    3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。
    3月9完成修改提交
    3月13号再次 Under review，
    3月20号审核完成
    3月23号收到 Accept 邮件。
    3月25号完成校稿
    3月29文章 Online

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2020-10-09 singshoe

    审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0
    偏重的研究方向：分子生物学;细胞生物学;肿瘤
    经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！
    Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead.
    Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal.

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2020-04-29 张丽瑾

    收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？

    10

    展开10条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2023-06-30 医路晋升 来自北京

    IF：1.4，又站起来了！

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-02-21 ms4000000175020740

    投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2023-01-25 ms4000001705670644 来自广东省

    好难啊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-31 agile

    偏重的研究方向：肿瘤
    经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 衣谷

    除文章内容和质量外，选刊时还需注意什么？

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2284141, encodeId=80e822841417f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤免疫<br>经验分享：7.29投稿，9.21小修，目前还没二审消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd39840580, createdName=ms7000000850384226, createdTime=Thu Oct 09 17:06:06 CST 2025, time=2025-10-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2279446, encodeId=287122e9446f9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：临床病理机制<br>经验分享：今年1月8号投了稿<br>1月15号收到格式修改提醒，调整后当天重新提交，<br>1月20号状态更新为 With editor<br>1月29号进入 Under review 阶段。<br>3月1号显示 Required reviews complete，<br>3月6号收到 Minor revision 通知，两位审稿人主要针对实验数据补充和病理图像分析提了建议，都很贴合临床病理研究实际。<br>3月9完成修改提交<br>3月13号再次 Under review，<br>3月20号审核完成<br>3月23号收到 Accept 邮件。<br>3月25号完成校稿<br>3月29文章 Online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 17:04:14 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=890858, encodeId=6316890858df, content=审稿速度:2.0 | 投稿命中率:100.0 | 版面费用:1580.0<br>偏重的研究方向：分子生物学;细胞生物学;肿瘤<br>经验分享：最垃圾的杂志，没有之一。投稿交了一份版面费，撤稿又交一份，而且比发表的版面费还贵，学生们不懂，吃了个哑巴亏。请大家远离这个垃圾杂志！看看人家的回复！<br>Since your paper had already been published, it cannot be withdrawn, but has to be retracted instead. <br>Please online submit a Retraction Statement which will be reviewed editorially to decide if the request for retraction is justified. If accepted, then the Retraction Statement must be processed and published which requires the regular publication fee to be paid. As you know, Retracting a published paper takes a lot more works than publishing a new regular paper which is very damaging and detrimental to both authors and the journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=368, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24e07712, createdName=singshoe, createdTime=Fri Oct 09 19:28:51 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589954, encodeId=95f058995470, content=收到了文章接收的邮件，让缴费，但没收到invoice的邮件呢，有一样的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=378, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=791b5313853, createdName=张丽瑾, createdTime=Wed Apr 29 00:00:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145644, encodeId=f2b9214564487, content=IF：1.4，又站起来了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200628/1100acdca53f4020b37a995c62cadf50/cfb5e0230e744dea9c07b62184d634de.jpg, createdBy=916e1609090, createdName=医路晋升, createdTime=Fri Jun 30 12:45:59 CST 2023, time=2023-06-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1195606, encodeId=95ef119560614, content=投稿一个星期了，目前处于Under Review，但是今天才发现没有收到投稿成功的邮件，请问这是为什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a06389737, createdName=ms4000000175020740, createdTime=Mon Feb 21 10:40:54 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111447, encodeId=117c211144ed3, content=好难啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad9b5384212, createdName=ms4000001705670644, createdTime=Wed Jan 25 21:51:32 CST 2023, time=2023-01-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1179235, encodeId=360d11e92355d, content=偏重的研究方向：肿瘤<br>经验分享：2021年《国际期刊预警名单（试行）》正式发布。 International Journal of Clinical and Experimental Pathology (IJCEP)已不在该预警名单中。 具体内容请参照https://mp.weixin.qq.com/s/dEIsgG3tCZRoWQBZ8UEJQA, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e982088871, createdName=agile, createdTime=Fri Dec 31 12:07:45 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104649, encodeId=8188110464997, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104650, encodeId=cb30110465055, content=老牌期刊和新出版期刊是否都要选一些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 MS68862005

    老牌期刊和新出版期刊是否都要选一些？

    1

    展开1条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分